PRRT2 and cancer: Both gain- and loss-of function PKC mutations are associated with diseased states, as reported recently for certain cancers (Antal et al., 2015b; Parker et al., 2021) and neurodegenerative disorders (Alfonso et al., 2016; Callender et al., 2018).